U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07065279) titled 'JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies' on June 25.
Brief Summary: This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B-cell Malignancies.
It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B-cell Malignancies.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
B-cell Malignancies
Intervention:
DRUG: JY231 Injection
Patients were enrolled and given a single dose of JY231 injection intrav...